mobileImage

Evermine50

An advanced drug-eluting stent designed for optimal coronary artery disease treatment

Breakthrough in DES Technology:

Designed to promote early vascular healing, this advanced stent features an ultra-low strut thickness of around 50μm, minimizing vessel irritation while enhancing endothelialization. Its innovative structure incorporates a variable strut width and crown design, ensuring an optimal balance between flexibility and radial strength, with a robust performance of 1.1 bar. The hybrid cell design offers the best of both worlds—open cells in the middle enable seamless side-branch access, while closed cells at the ends provide superior scaffolding and conformability. Coated with the clinically established drug everolimus and a biodegradable polymer, this stent ensures proven long-term safety and efficacy, supporting superior patient outcomes.

*Bench test data on file at Meril Life Sciences

Key Features

0.016 Tip Entry Profile

Elongated distal tip 7mm, acts like a micro-catheter. Allowing low profile lesion entry

0.039 Crossing Pofile

Proven Everolimus Drug with BioPoly-biodegradable and biocompatible polymer

  • >500 all comer patients studied in 3 clinical studies with follow-up upto 1 year. Ongoing robust clinical trial programme.
  • 0% Stent Thrombosis at 6 months and 1 year in all comer patient population. 
  • Low mace rate of < 2% at 1 year.

Coronary Angioplasty - Treatment for Coronary Artery Disease

Narrowing of a heart's blood vessel can result in its complete blockage and can progress gradually or can occur suddenly resulting in a heart attack, known as a myocardial infarction. Angioplasty is a procedure to widen the coronary artery and restore the blood flow. Know more here.

Product Details

View
Clinical Data

Specification

Size Chart

Similar Products

BioMime

BioMime

Metafor

Metafor

Mozec Rx PTCA BDC

Mozec Rx PTCA BDC

1 / 11

Connect with Meril